AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06501924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical minoxidil 5%
Description: Topical minoxidil 5%
Study NCT06501924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-002
Description: Topical Alpha 1 Agonist (GRAS)
Study NCT06501924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study NCT06686498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery adapted to suicidal behavior (IMR-ACS)
Description: Illness Management and Recovery adapted to suicidal behavior (IMR-ACS) is a protocolized clinical intervention in a brief group format aimed at people at risk of suicide. Specifically, people who have had more than two attempts in their lifetime are called repeaters. For its construction, we relied on the Spanish version of the Illness Management and Recovery IMR, developed by the Spanish Nursing Association, adapted to the field of suicidal behavior, taking as a reference the model of personal recovery from suicide attempt proposed by Sokol et al.~The goals of IMR-ACS are to 1) know the warning signs of a suicidal crisis, 2) implement strategies to manage the suicidal crisis, 3) foster social support among peers, 4) formulate goals for recovery from a suicidal crisis, and 5) seek help and make informed decisions in the event of a suicidal crisis.~IMR-ACS is a complementary intervention to the usual treatments.
Study NCT06691763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pythagorean Self-Awareness Intervention for stress management and health promotion
Description: Pythagorean Self-Awareness is a holistic stress magement program that combines cognitive reconstruction and the implementation of the 6 pillars of life-style medicine depending on the targeted population.
Study NCT06691516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: horizontal and vertical bone augmentation using computer guided cortical shell technique
Description: Computer-guided cortical shell technique in anterior mandible 3d defect using bone harvesting guide and fixation guides
Study NCT06691516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free hand cortical shell technique in anterior 3d defect
Description: vertical and horizontal ridge augmentation in anterior mandible using free hand cortical shell technique
Study NCT06070532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)
Description: 100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
Study NCT06501924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study NCT06501924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Topical Solution
Description: Placebo Topical Solution
Study NCT05968638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular Diet
Description: Regular Diet
Study NCT05968638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet
Description: Ketogenic Diet
Study NCT05986188 — intervention group
Intervention type: OTHER
Intervention: Pathways to Potential
Description: Pathways to Potential stations MDHHS caseworkers, called success coaches, in local elementary, middle, and high schools. After identifying a social or material need that is a barrier to school attendance (e.g., transportation barriers, caregiver unemployment), success coaches connect students and families to community resources and public assistance.
Study NCT05243251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine 5 MG
Description: , Olanzapine (OLZ) is an atypical antipsychotic agent that blocks multiple neurotransmitters: dopamine at D1, D2, D3 and D4 brain receptors, serotonin at 5-HT2a , 5-HT2c, 5-HT3, and 5-HT6receptors, catecholamines at alpha 1 adrenergic receptors, acetylcholine at muscarinic receptors, and histamine at H1 receptors is suggested to have a valuable role in CAC
Study NCT05243251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug
Study NCT00013195 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Care
Study NCT06248320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigh ventilation
Description: Sigh breaths were delivered from intubation to extubation. Intervention primarily conducted in the following three stages: 1. From intubation to surgical opening of the chest cavity; 2. From the surgical closure of the chest cavity close and continue unit the operating room exiting; 3. From Intensive Care Unit (ICU) arrival to Spontaneous breathing trial (SBT) start.
Study NCT05606614 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TSHA-102
Description: TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
Study NCT05945732 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab deruxtecan
Description: This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~Trastuzumab (T-DXd) to be administered according to the SmPC.~Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC.
Study NCT05847686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Participate in therapy visits
Study NCT05847686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Given PO
Study NCT05847686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05346562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol tablets
Study NCT05346562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cannabidiol-matched placebo tablets
Study NCT04345939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection method
Description: Different methods for pathogen diagnosis
Study NCT06513195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasound-guided portal pressure measurement
Description: The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.
Study NCT05964738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretics withdrawal
Description: Diuretics that not have been demonstrated improve survival in chronic HFrEF are withdrawn
Study NCT05964738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics maintenance
Description: Any diuretic could be used
Study NCT05530512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: acupuncture needling and stimulation are applied for 30 min
Study NCT06512909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses Application
Description: A video containing relaxing nature images will be shown to a group via VR. Intramuscular injection will begin three minutes after the individual starts watching the video, and the procedure will be performed while continuing to watch the video.
Study NCT06512909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Ball Application
Description: One group will be given a stress ball in the hand on the side where the intramuscular injection will be administered. Three minutes after the individual starts squeezing the ball, intramuscular injection will begin and the procedure will be performed while squeezing the ball.
Study NCT05496920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FD-PET/CT
Description: Standard of care PET/CT with full dose (FD) of the radiopharmaceutical
Study NCT05496920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LD-PET/CT
Description: Additional low dose PET/CT performed within protocol defined time frame LD-PET/CT with additional ultra-low dose CT-less reconstruction
Study NCT05221554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-navigated THA surgery
Description: Navigation software coupled with real-time modeling software will be used to plan optimal acetabular cup for patients undergoing THA.
Study NCT05221554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care THA surgery
Description: Patients already underwent THA procedure with manual placement of acetabular cup with conventional instrumentation.
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (HER2 expression group) : Vedicetumab (2.5mg/kg, Q2w) alone or combined with platinum-based chemotherapy drugs (carboplatin 200-250mg/m2, Q2w or cisplatin 50mg/m2, Q2w) Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (HER2 expression group) : Vedicetumab monotherapy (2mg/kg, IV, Q2w) or vedicetumab (2mg/kg, IV, Q2w) combined with immune checkpoint inhibitors (triprilizumab 3mg/kg, IV, Q2w, etc.) or vedicetumab (2mg/kg, IV, Q2W, etc.) Q2w) in combination with oral HER2 TKI (pyrrotinib 400mg po qd and other drugs) or Vedicetsol in combination with platinum-based chemotherapy drugs of the doctor's choice (carboplatin 200-250mg/m2, intravenous drip, Q2w or cisplatin 50mg/m2, intravenous drip, Q2w).
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotinib or enttraitinib
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po;
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiandrogen drug treatment
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po ± Abiraterone 1000mg po qdor antiandrogen drug treatment; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po or antiandrogen drug treatment;
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESG401
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(TROP-2 positive group) : ESG401 16mg/kg,D1，D8 ,D15 ivgtt Q4w.~Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(TROP-2 positive group) : ESG401 16mg/kg,D1，D8 ,D15 ivgtt Q4w
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: small molecule multi-target tyrosine kinase inhibitors± Chemioterapy
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(ACC group)and Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(ACC group): Adenoid cystadenocarcinoma given acitinib (5mg bid po) or apatinib (500mg qd po) or Renvastinib (24mg qd po) or sorafenib (400mg bid po) or anrotinib (12mg qd) po) or other small molecule multi-target tyrosine kinase inhibitors± chemotherapy(albumin paclitaxel :160mg/m2 Q2w or 260mg/m2 Q3w, combined with platinum-based chemotherapy drugs of the doctor's choice: cisplatin 50mg/m2, Q2w or 75mg/m2, Q3w, or carboplatin 200-250mg/m2 Q2w or 350mg/m2 q3w, static).
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel with platinum
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(no target and other groups) : albumin paclitaxel :160mg/m2 Q2w or 260mg/m2 Q3w, combined with platinum-based chemotherapy drugs of the doctor's choice: cisplatin 50mg/m2, Q2w or 75mg/m2, Q3w, or carboplatin 200-250mg/m2 Q2w or 350mg/m2 q3w, ; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(no target and other groups) : albumin paclitaxel :160mg/m2 Q2w or 260mg/m2 Q3w, combined with platinum-based chemotherapy drugs of the doctor's choice: cisplatin 50mg/m2, Q2w or 75mg/m2, Q3w, or carboplatin 200-250mg/m2 Q2w or 350mg/m2 q3w,
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR-positive group
Description: Abesili 150mg bid po or Piperoxili 125mg qd po, etc CDK4/6 inhibitors + aromatase inhibitors (letrozole 2.5mg qd po or anastrozole 1mg qd po or Exemestane 20mg qd po) or Fluvis Group 0.5mg im q4w;
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K mutant group
Description: PI3K inhibitors such as Apelis 300mg qd po + Fluvis group 0.5mg im q4w, etc
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homologous Recombination repair defect group
Description: Olapalil 300mg bid po or Nilapalil 300mgPARP inhibitors such as qd po or fluzopalil 150mg bid po or pamipalil 60mg bid po;
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nectin-4 ADC group
Description: Veentumab 1.25mg/kg ivgtt d1d8d15(Max Nectin-4 ADC± immune checkpoint inhibitor (pabolizumab 200mg, pabolizumab 200mg,Carrilizumab 200mg, Q3w or triplizumab 240mg, Q3w, etc.);
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivoximab group
Description: Ivoximab 20mg/kg+ albumin paclitaxel 260mg/m2+Cisplatin 75mg/m2 ivgtt q3w
Study NCT06145308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalolito vorellizumab group
Description: Apalolito vorellizumab 5mg/kg+ Platinum dual drug (white purple 260mg/m2 Q3w/ Paclitaxel liposome 175mg/m2/ Docetaxel 75mg/m2/ vinorelbine 25mg/m2 + cisplatin 75mg/m2, Q3w or carboplatin 350mg/m2 q3w) + bevacizumab 5mg/kg;
Study NCT04620603 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Rate Brachytherapy (LDR)
Description: LDR on treatment day 1
Study NCT04620603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-Care Immunotherapy
Description: Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.
Study NCT06474936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food education
Description: During the consultations are planned at least 6 nutritional education sessions in which the general nutritional advice provided by the Mediterranean Diet will be exposed, and some paper materials can be delivered according to the needs of each individual. 3 in-person meetings and 3 online meetings are planned. Both online and in-person food education sessions will be conducted by experienced nutrition experts monthly. These sessions will cover a range of topics, including the principles of the Mediterranean diet, practical cooking skills, meal-planning strategies, and tips for incorporating Mediterranean-style dishes into daily life
Study NCT05635838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study NCT05635838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle cream
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Study NCT05415280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based stress reduction
Description: The aim of the psychological intervention to reduce the mental health problems of the participants.
Study NCT05415280 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based stress reduction
Description: The aim of the psychological intervention to reduce the mental health problems of the participants.
Study NCT05020444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TriPRIL CAR T Cells
Description: Intravenous infusion
Study NCT05020444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous infusion
Study NCT05020444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous infusion
Study NCT05636254 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Brain and spine
Description: * MRI Brain~* Ax T2 TSE~* 3D Sag T1~* Ax DWI~* 3D Sag Flair~* Ax SWI~* Post-gad 3D Sag T1~* 3D TOF Circle-of-Willis~* MRI Spine~* Sag T2 whole spine (2 stations)~* Post-gad Sag T1 whole spine (2 stations)
Study NCT05374941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injectable and wearable neurostimulator for the hypoglossal nerve
Description: Temporary placement of injectable and wearable neurostimulator for the hypoglossal nerve
Study NCT05615714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paresthesia-free Peripheral Nerve Field Stimulation
Description: High frequency and sub-paresthesia threshold intensity parameters will be used for paresthesia-free stimulation of trigeminal nerve branches.
Study NCT05615714 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Stimulation will be turned off.
Study NCT05261451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workshop
Description: Participants will engage in three 1 hour workshops about trauma informed care. They will complete pre and post measure before engaging in the workshops
Study NCT05636254 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reference standard diagnostic criteria
Description: Diagnostic criteria-TBM~* Microbiologic evidence of TB in CSF~* Microbiologic evidence of TB from pulmonary or extrapulmonary sites~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication suggestive of tuberculosis~* Other relevant investigations like CSF analysis not suggestive of alternative diagnosis such as neurocysticercosis/cryptococcal/other fungal infections/other causes of chronic meningitis such as brucella/ nocardia/ syphilis/recurrent viral meningitis/ carcinomatous/ lymphomatous meningitis or non infective causes such as sarcoidoisis/sub-arachnoid hemorrhage etc.~* Reasonable clinical certainty OR allied investigations such as CXR/CECT chest/abdomen/PET CT as per clinical indication ruling out competing diagnoses~* Patients who develop features or test results suggestive of alternative diagnosis with will be considered to be not due to tubercular meningitis
Study NCT06492109 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Experimental sleep deprivation
Description: Cognitive assessment of subjects: This study will collect the Mini-Mental State Examination (MMSE) results as a supplement to the Montreal Cognitive Assessment (MoCA). The sleep status of subjects will be screened using the Morningness-Eveningness Questionnaire (MEQ), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS). Subjects must maintain regular sleep and diet before sample collection. Peripheral blood samples will be taken the day before, the day of, and the day after acute sleep deprivation, whether voluntary or involuntary, along with anxiety and depression assessments. For chronic sleep deprivation (≥7 days), blood samples will be collected before and after the deprivation period, with anxiety, depression, and cognitive assessments. Voluntary sleep deprivation occurs under experimental conditions, while involuntary deprivation is due to factors like age or shift work.
Study NCT06449690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dog-assisted therapy
Description: Dog-assisted therapy consists of the search for positive interactions resulting from the intentional human-animal relationship in the educational, therapeutic or social fields, practices as they are conducted in educational and medico-social institutions for example.
Study NCT06449690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occupational activities
Description: Occupational activities consist of origami, relaxation, sports or board games sessions.
Study NCT06103552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Lifestyle Options for Orthopedic Mobility (BLOOM)
Description: This intervention is a lifestyle program with includes dietary coaching from a dietitian and regular doctor appointments with a bariatric medicine specialist over the course of 24 weeks.
Study NCT05601596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of menstrual blood to predict endometriosis
Description: Menstrual blood from controls and symptomatic cases will be analyzed using single cell RNA-sequencing to develop a panel of biomarkers that can be developed into a screening test or diagnostic test for endometriosis.
Study NCT05140759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automated continual water removal system
Description: The device removes excess fluids in heart failure patients with diuretic resistance